<code id='555AA1CFCE'></code><style id='555AA1CFCE'></style>
    • <acronym id='555AA1CFCE'></acronym>
      <center id='555AA1CFCE'><center id='555AA1CFCE'><tfoot id='555AA1CFCE'></tfoot></center><abbr id='555AA1CFCE'><dir id='555AA1CFCE'><tfoot id='555AA1CFCE'></tfoot><noframes id='555AA1CFCE'>

    • <optgroup id='555AA1CFCE'><strike id='555AA1CFCE'><sup id='555AA1CFCE'></sup></strike><code id='555AA1CFCE'></code></optgroup>
        1. <b id='555AA1CFCE'><label id='555AA1CFCE'><select id='555AA1CFCE'><dt id='555AA1CFCE'><span id='555AA1CFCE'></span></dt></select></label></b><u id='555AA1CFCE'></u>
          <i id='555AA1CFCE'><strike id='555AA1CFCE'><tt id='555AA1CFCE'><pre id='555AA1CFCE'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:71496

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          comprehensive

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          Gritstone Bio's cancer vaccine test, and more on Novartis' deal
          Gritstone Bio's cancer vaccine test, and more on Novartis' deal

          MollyFerguson/STATThisweek,IaddresspushbackIreceivedonmyNovartis-MorphoSyscolumn.Butfirst,apreviewof

          read more
          Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
          Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

          FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

          read more

          Why Novartis is going to walk from its acquisition of MorphoSys

          MollyFerguson/STATNovartissaidMondaythatitintendstobuyMorphoSysforjustunder$3billion.Thedealwillnotc